There are other approved drugs targeting C1-INH, and there are several other drugs in the pre-clinical and clinical trial pipeline, targeting C1r, C1s, C3, C3a, C5, C5a, C6, FH, FD, FB, FP, etc [41], and soon we expect to have approval for clinical use a pool of several drugs against complement-mediated inflammatory and autoimmune diseases. The gene discussed is ELP1; the disease is autoimmune disease.